Jefferies sees Novo dropping 'at least' 10%-15% on obesity data - Yahoo Finance
Jefferies analyst Peter Welford anticipates Novo Nordisk shares to drop at least 10%-15% due to disappointing Phase III CagriSema obesity data, showing 20.4% weight loss and potential tolerability issues. The firm maintains an Underperform rating with an $81.50 price target.
Highlighted Terms
Related News
Jefferies sees Novo dropping 'at least' 10%-15% on obesity data - Yahoo Finance
Jefferies analyst Peter Welford anticipates Novo Nordisk shares to drop at least 10%-15% due to disappointing Phase III CagriSema obesity data, showing 20.4% weight loss and potential tolerability issues. The firm maintains an Underperform rating with an $81.50 price target.